CNS Lymphoma Diagnosis and Treatment
CNS Lymphoma Diagnosis and Treatment is a research topic within Neurology. Science Explorer counts 17k research works in it since 1950. 11.5% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the diagnosis, treatment, and management of primary central nervous system lymphoma (PCNSL). It covers various aspects such as prognostic scoring systems, chemotherapy and radiotherapy regimens, use of methotrexate and rituximab therapy, genetic features, neurological masquerade syndromes, and cognitive functions in PCNSL patients.
- Primary CNS Lymphoma
- Prognostic Scoring System
- Chemotherapy
- Radiotherapy
- Methotrexate
- Intravascular Lymphoma
- Rituximab Therapy
- Genetic Features
- Neurological Masquerade Syndromes
- Cognitive Functions
- Research works
- 17k fractional, since 1950
- In the world top 10%
- 1.9k per year above
- Top-10% rate
- 11.5% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +24% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead CNS Lymphoma Diagnosis and Treatment research?
By volume, the United States and China publish the most (835 and 583 works in 2022–2025).
By volume, 2022–2025
- 1 United States 835 works
- 2 China 583 works
- 3 Japan 276 works
- 4 India 160 works
- 5 Germany 131 works
- 6 France 127 works
- 7 Italy 112 works
- 8 United Kingdom 87 works
- 9 Spain 76 works
- 10 South Korea 76 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead CNS Lymphoma Diagnosis and Treatment research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most CNS Lymphoma Diagnosis and Treatment research, followed by Capital Medical University and Memorial Sloan Kettering Cancer Center.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 26 works
- 2 Capital Medical UniversityChina 24 works
- 3 Memorial Sloan Kettering Cancer CenterUnited States 23 works
- 4 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 21 works
- 5 Peking Union Medical College HospitalChina 14 works
- 6 Mayo Clinic in ArizonaUnited States 14 works
- 7 Mayo Clinic in FloridaUnited States 13 works
- 8 Cleveland ClinicUnited States 12 works
- 9 Mayo ClinicUnited States 12 works
- 10 University of PennsylvaniaUnited States 11 works
Who are the leading researchers in CNS Lymphoma Diagnosis and Treatment?
The most-cited researchers publishing on CNS Lymphoma Diagnosis and Treatment include Elı́as Campo, Michael Weller and David Cunningham.
- 1 Elı́as Campo Spain 3k citations
- 2 Michael Weller Switzerland 2.7k citations
- 3 David Cunningham United Kingdom 2.5k citations
- 4 Elaine S. Jaffe United States 2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is CNS Lymphoma Diagnosis and Treatment research done?
The largest centres of CNS Lymphoma Diagnosis and Treatment research in 2022–2025 are Beijing (China), Tokyo (Japan), Shanghai (China) and New York (United States).
Largest cities, 2022–2025
Where is the best place to study CNS Lymphoma Diagnosis and Treatment?
Among universities, judged by research, Capital Medical University, University of Pennsylvania and Nanjing Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Capital Medical UniversityChina | 68.1 | 7.5% | 13.1× | 24 | +95.4% |
| 2 | University of PennsylvaniaUnited States | 53.3 | 16.4% | 3.9× | 11 | +37.4% |
| 3 | Nanjing Medical UniversityChina | 48.3 | 11.1% | 5.5× | 9 | +180.0% |
| 4 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 47.4 | 4.8% | 7.1× | 21 | +9.1% |
| 5 | Sichuan UniversityChina | 36.2 | 7.3% | 2.0× | 11 | +283.8% |
| 6 | Post Graduate Institute of Medical Education and ResearchIndia | 33.6 | 1.9% | 9.1× | 9 | +65.5% |
| 7 | Saitama Medical UniversityJapan | 30.7 | 1.8% | 40.3× | 9 | +6.2% |
| 8 | Sun Yat-sen UniversityChina | 30.3 | 10.0% | 2.2× | 11 | -7.4% |
| 9 | Fudan UniversityChina | 27.8 | 5.5% | 2.8× | 10 | +50.3% |
| 10 | All India Institute of Medical SciencesIndia | 20.0 | 0.0% | 5.2× | 10 | +78.8% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is CNS Lymphoma Diagnosis and Treatment research growing?
Output in 2018–2022 was 24% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are CNS Lymphoma Diagnosis and Treatment.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.